menu
    • menu

    Company profile for Syntis Bio

    NEW Drugs in Dev: 1
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Syntis Bio is a clinical-stage biopharmaceutical company redefining oral therapy. We harness the small intestine's unique biology with our proprietary SYNT™ technology, a transient polymer coating that controls nutrient uptake and enhances drug delivery. Our lead program, SYNT-101, is a once-daily oral pill for obesity designed to mimic the metabolic benefits of gastric bypass surgery. We are leveraging this platform to deve...
    Syntis Bio is a clinical-stage biopharmaceutical company redefining oral therapy. We harness the small intestine's unique biology with our proprietary SYNT™ technology, a transient polymer coating that controls nutrient uptake and enhances drug delivery. Our lead program, SYNT-101, is a once-daily oral pill for obesity designed to mimic the metabolic benefits of gastric bypass surgery. We are leveraging this platform to develop accessible and effective oral treatments for a wide range of conditions, from prevalent metabolic diseases to rare genetic disorders. Syntis Bio is headquartered in Boston.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Syntis BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    135 Morrissey Boulevard Ste 101A Boston, MA 02125
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://syntis.bio/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/syntis-bio/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Syntis Bio Doses First Patient in SYNT-101 Trial
    Syntis Bio Doses First Patient in SYNT-101 Trial

    03 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260303379293/en/Syntis-Bio-Announces-First-Patient-Dosed-in-Phase-11b-Clinical-Trial-of-SYNT-101-in-Obesity-and-Key-Leadership-Additions

    BUSINESSWIRE
    03 Mar 2026
    Share Share
    Syntis Bio secures $38M to speed up oral therapies for obesity
    Syntis Bio secures $38M to speed up oral therapies for obesity

    01 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250701704610/en/Syntis-Bio-Closes-%2438-Million-Financing-to-Accelerate-Oral-Therapies-for-Obesity-and-Rare-Diseases

    BUSINESSWIRE
    01 Jul 2025
    Share Share
    Syntis Bio Releases New Data on SYNT-101 for Obesity at European
    Syntis Bio Releases New Data on SYNT-101 for Obesity at European

    10 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250410377442/en/Syntis-Bio-Releases-New-Data-Supporting-Potential-of-SYNT-101-as-a-Once-Daily-Oral-Treatment-for-Obesity-at-European-Congress-on-Obesity-and-Weight-Management

    BUSINESSWIRE
    10 Apr 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search